Watashi Koichi, Shionoya Kaho, Kobayashi Chisa, Morita Takeshi
Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan.
Department of Applied Biological Science, Tokyo University of Science, Noda, Japan.
Nat Rev Microbiol. 2025 May;23(5):318-331. doi: 10.1038/s41579-024-01121-2. Epub 2024 Nov 21.
Hepatitis B virus (HBV) entry is the initial step of viral infection, leading to the formation of covalently closed circular DNA, which is a molecular reservoir of viral persistence and a key obstacle for HBV cure. The restricted entry of HBV into specific cell types determines the nature of HBV, which has a narrow host range in tissues and species. Hepatitis D virus (HDV) shares viral surface antigens with HBV and thus follows a similar entry mechanism at its early stages. In late 2012, sodium taurocholate cotransporting polypeptide was discovered as an HBV and HDV entry receptor. Since then, the mechanisms of HBV and HDV entry have been extensively analysed. These analyses have expanded our understanding of HBV and HDV host tropism and have provided new strategies for the development of antiviral agents. Notably, the structures of sodium taurocholate cotransporting polypeptide and its interaction with the 2-48 amino acid region of viral preS1 have been recently solved. These findings will stimulate further entry studies. In this Review, we summarize current understanding of HBV and HDV entry and future perspectives.
乙肝病毒(HBV)进入细胞是病毒感染的起始步骤,会导致共价闭合环状DNA的形成,而共价闭合环状DNA是病毒持续存在的分子储存库,也是治愈乙肝的关键障碍。HBV进入特定细胞类型的限制决定了其特性,即它在组织和物种中的宿主范围较窄。丁型肝炎病毒(HDV)与HBV共享病毒表面抗原,因此在早期阶段遵循类似的进入机制。2012年末,牛磺胆酸钠共转运多肽被发现是HBV和HDV的进入受体。自那时起,HBV和HDV的进入机制得到了广泛分析。这些分析扩展了我们对HBV和HDV宿主嗜性的理解,并为抗病毒药物的开发提供了新策略。值得注意的是,牛磺胆酸钠共转运多肽的结构及其与病毒前S1区2 - 48氨基酸区域的相互作用最近已得到解析。这些发现将推动进一步的进入研究。在本综述中,我们总结了目前对HBV和HDV进入的理解以及未来展望。